Randomised Phase II Trial of Irinotecan/Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab (DIN) in Children with Refractory or Relapsed Neuroblastoma: A Report from The Children’s Oncology Group (COG)

BACKGROUND: Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide (I/T) has activity in these patients, and the toxicity profile of I/T makes it an excellent backbone for study of new agents. Temsirolimus (TEM) and dinutuximab (DI...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet Oncol
Glavni autori: Mody, Rajen, Naranjo, Arlene, Van Ryn, Collin, Yu, Alice L., London, Wendy B., Shulkin, Barry L., Parisi, Marguerite T., Servaes, Sabah-E-Noor, Diccianni, Mitchell B., Sondel, Paul M., Maris, John M., Park, Julie R., Bagatell, Rochelle
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5527694/
https://ncbi.nlm.nih.gov/pubmed/28549783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30355-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items